Skip to main content

clindamycin

Generic: CLINDAMYCIN PHOSPHATE·Brand: ANTIROBE, Acanya, CLEOCIN, CLEOCIN HYDROCHLORIDE, CLEOCIN PHOSPHATE, CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLEOCIN T, CLINDA-DERM, CLINDAGEL, CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDESSE, CLINDETS, Cabtreo, Cleocin, Cleocin-T, Clinda-Guard, ClindaCure, Clindacin, Clindagel, Clindamax, Clindesse, Clintabs, EVOCLIN, Evoclin, Neuac, Onexton, Veltin, XACIATO, Xaciato, Ziana, Zydaclin

clindamycin: 3 clinical trials tracked.

clindamycin evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about clindamycin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 2 study sponsors

Related indications

Acne Vulgaris
Clinical Trials (3)

Satisfaction, Adherence, Effectiveness, and Safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Treatment in Patients With Acne Vulgaris: A Canadian Prospective Phase IV Study (CHARM)

NCT07205107·BHC
Active, not recruiting

Primary endpoint: Treatment Satisfaction at Week-12 as assessed by DermSat-7

Observational200 targetStarted 2025-10Completion 2026-0819 sites · CanadaBausch Health Americas, Inc.

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

NCT06120140·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment

InterventionalRandomizedopen305 targetStarted 2024-02Completion 2032-0150 sites · Argentina, Brazil, China, United StatesJanssen Research & Development, LLC

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118·N/A·INSM
Recruiting

Primary endpoint: M/P ratio

Observational1,600 targetStarted 2018-10Completion 2027-0722 sites · Canada, United StatesDuke University